@article{ATM31814,
author = {Xingzhe D. Li and Charles B. Simone II},
title = {The inflammatory response from stereotactic body proton therapy versus stereotactic body radiation therapy: implications from early stage non-small cell lung cancer},
journal = {Annals of Translational Medicine},
volume = {7},
number = {Suppl 8},
year = {2019},
keywords = {},
abstract = {Lung cancer is the second most common noncutaneous cancer and the deadliest cancer in the United States (US) with 228,150 estimated new cases in 2019 (1). About 87% of lung cancers diagnosed in the US are non-small cell lung cancer (NSCLC), which currently has a 5-year overall survival (OS) rate of 23% across all stages, ranging from 57% for stage I to 4% for stage IV diseases (2).},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/31814}
}